tiprankstipranks
Palvella Therapeutics, Inc. (PVLA)
NASDAQ:PVLA
US Market
Want to see PVLA full AI Analyst Report?

Palvella Therapeutics (PVLA) Stock Forecast & Price Target

784 Followers
See the Price Targets and Ratings of:

PVLA Analyst Ratings

Strong Buy
14Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Palvella
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PVLA Stock 12 Month Forecast

Average Price Target

$231.00
▲(77.68% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Palvella Therapeutics in the last 3 months. The average price target is $231.00 with a high forecast of $270.00 and a low forecast of $209.00. The average price target represents a 77.68% change from the last price of $130.01.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","146":"$146","271":"$271","83.5":"$83.5","208.5":"$208.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":270,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$270.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":231,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$231.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":209,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$209.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,83.5,146,208.5,271],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,126.84,137.8523076923077,148.86461538461538,159.87692307692308,170.88923076923078,181.90153846153845,192.91384615384615,203.92615384615385,214.93846153846152,225.95076923076923,236.96307692307693,247.9753846153846,258.9876923076923,{"y":270,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,126.84,134.8523076923077,142.86461538461538,150.87692307692308,158.88923076923078,166.90153846153845,174.91384615384615,182.92615384615385,190.93846153846152,198.95076923076923,206.96307692307693,214.9753846153846,222.9876923076923,{"y":231,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,126.84,133.16,139.48,145.8,152.12,158.44,164.76,171.07999999999998,177.4,183.72,190.04,196.36,202.68,{"y":209,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.67,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.61,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.38,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.84,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$270.00Average Price Target$231.00Lowest Price Target$209.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on PVLA
Canaccord Genuity
Canaccord Genuity
$227
Buy
74.60%
Upside
Reiterated
05/18/26
Canaccord Genuity Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)
Stephens
$220
Buy
69.22%
Upside
Initiated
05/11/26
Analyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential
LifeSci Capital Analyst forecast on PVLA
LifeSci Capital
LifeSci Capital
$225
Buy
73.06%
Upside
Assigned
05/09/26
Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (NYSE MKT: ARMP), Palvella Therapeutics (NASDAQ: PVLA) and MBX Biosciences, Inc. (NASDAQ: MBX)
TD Cowen Analyst forecast on PVLA
TD Cowen
TD Cowen
$267
Buy
105.37%
Upside
Reiterated
05/08/26
Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), Palvella Therapeutics (PVLA)
Oppenheimer Analyst forecast on PVLA
Oppenheimer
Oppenheimer
$210
Buy
61.53%
Upside
Reiterated
05/08/26
Palvella Therapeutics (PVLA) Receives a Buy from Oppenheimer
Mizuho Securities Analyst forecast on PVLA
Mizuho Securities
Mizuho Securities
$250$240
Buy
84.60%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Enovis (NYSE: ENOV) and Insmed (NASDAQ: INSM)
Truist Financial Analyst forecast on PVLA
Truist Financial
Truist Financial
$210
Buy
61.53%
Upside
Reiterated
05/08/26
Palvella Therapeutics (PVLA) Gets a Buy from Truist Financial
H.C. Wainwright Analyst forecast on PVLA
H.C. Wainwright
H.C. Wainwright
$239.7$270
Buy
107.68%
Upside
Reiterated
05/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Chardan Capital Analyst forecast on PVLA
Chardan Capital
Chardan Capital
$240
Buy
84.60%
Upside
Reiterated
05/07/26
Analysts Are Bullish on Top Healthcare Stocks: OmniAb (OABI), Gilead Sciences (GILD)
BTIG
$215
Buy
65.37%
Upside
Reiterated
04/01/26
Palvella Therapeutics (PVLA) Gets a Buy from BTIG
Craig-Hallum Analyst forecast on PVLA
Craig-Hallum
Craig-Hallum
Buy
Reiterated
03/19/26
Analysts Offer Insights on Healthcare Companies: Spectral AI (NASDAQ: MDAI) and Palvella Therapeutics (NASDAQ: PVLA)
Clear Street Analyst forecast on PVLA
Clear Street
Clear Street
$200$220
Buy
69.22%
Upside
Reiterated
03/02/26
Palvella Therapeutics (PVLA) Receives a Buy from Clear Street
Stifel Nicolaus Analyst forecast on PVLA
Stifel Nicolaus
Stifel Nicolaus
$180$250
Buy
92.29%
Upside
Reiterated
02/24/26
Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Warby Parker (WRBY)
JonesTrading Analyst forecast on PVLA
JonesTrading
JonesTrading
$143$209
Buy
60.76%
Upside
Reiterated
02/24/26
Palvella Therapeutics price target raised to $209 from $143 at JonesResearchPalvella Therapeutics price target raised to $209 from $143 at JonesResearch
Cantor Fitzgerald Analyst forecast on PVLA
Cantor Fitzgerald
Cantor Fitzgerald
$200$210
Buy
61.53%
Upside
Reiterated
12/15/25
Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on PVLA
Canaccord Genuity
Canaccord Genuity
$227
Buy
74.60%
Upside
Reiterated
05/18/26
Canaccord Genuity Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)
Stephens
$220
Buy
69.22%
Upside
Initiated
05/11/26
Analyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential
LifeSci Capital Analyst forecast on PVLA
LifeSci Capital
LifeSci Capital
$225
Buy
73.06%
Upside
Assigned
05/09/26
Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (NYSE MKT: ARMP), Palvella Therapeutics (NASDAQ: PVLA) and MBX Biosciences, Inc. (NASDAQ: MBX)
TD Cowen Analyst forecast on PVLA
TD Cowen
TD Cowen
$267
Buy
105.37%
Upside
Reiterated
05/08/26
Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), Palvella Therapeutics (PVLA)
Oppenheimer Analyst forecast on PVLA
Oppenheimer
Oppenheimer
$210
Buy
61.53%
Upside
Reiterated
05/08/26
Palvella Therapeutics (PVLA) Receives a Buy from Oppenheimer
Mizuho Securities Analyst forecast on PVLA
Mizuho Securities
Mizuho Securities
$250$240
Buy
84.60%
Upside
Reiterated
05/08/26
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Enovis (NYSE: ENOV) and Insmed (NASDAQ: INSM)
Truist Financial Analyst forecast on PVLA
Truist Financial
Truist Financial
$210
Buy
61.53%
Upside
Reiterated
05/08/26
Palvella Therapeutics (PVLA) Gets a Buy from Truist Financial
H.C. Wainwright Analyst forecast on PVLA
H.C. Wainwright
H.C. Wainwright
$239.7$270
Buy
107.68%
Upside
Reiterated
05/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Chardan Capital Analyst forecast on PVLA
Chardan Capital
Chardan Capital
$240
Buy
84.60%
Upside
Reiterated
05/07/26
Analysts Are Bullish on Top Healthcare Stocks: OmniAb (OABI), Gilead Sciences (GILD)
BTIG
$215
Buy
65.37%
Upside
Reiterated
04/01/26
Palvella Therapeutics (PVLA) Gets a Buy from BTIG
Craig-Hallum Analyst forecast on PVLA
Craig-Hallum
Craig-Hallum
Buy
Reiterated
03/19/26
Analysts Offer Insights on Healthcare Companies: Spectral AI (NASDAQ: MDAI) and Palvella Therapeutics (NASDAQ: PVLA)
Clear Street Analyst forecast on PVLA
Clear Street
Clear Street
$200$220
Buy
69.22%
Upside
Reiterated
03/02/26
Palvella Therapeutics (PVLA) Receives a Buy from Clear Street
Stifel Nicolaus Analyst forecast on PVLA
Stifel Nicolaus
Stifel Nicolaus
$180$250
Buy
92.29%
Upside
Reiterated
02/24/26
Analysts' Top Healthcare Picks: Protara Therapeutics (TARA), Warby Parker (WRBY)
JonesTrading Analyst forecast on PVLA
JonesTrading
JonesTrading
$143$209
Buy
60.76%
Upside
Reiterated
02/24/26
Palvella Therapeutics price target raised to $209 from $143 at JonesResearchPalvella Therapeutics price target raised to $209 from $143 at JonesResearch
Cantor Fitzgerald Analyst forecast on PVLA
Cantor Fitzgerald
Cantor Fitzgerald
$200$210
Buy
61.53%
Upside
Reiterated
12/15/25
Palvella price target raised to $210 from $200 at Cantor FitzgeraldPalvella price target raised to $210 from $200 at Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Palvella Therapeutics

3 Months
Andrew FeinH.C. Wainwright
Success Rate
11/14 ratings generated profit
79%
Average Return
+58.28%
Copying Andrew Fein's trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +58.28% per trade.
1 Year
Andrew FeinH.C. Wainwright
Success Rate
12/14 ratings generated profit
86%
Average Return
+244.12%
Copying Andrew Fein's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +244.12% per trade.
2 Years
Andrew FeinH.C. Wainwright
Success Rate
12/14 ratings generated profit
86%
Average Return
+264.09%
Copying Andrew Fein's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +264.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PVLA Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
28
39
34
36
27
Buy
16
7
5
2
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
44
46
39
38
28
In the current month, PVLA has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PVLA average Analyst price target in the past 3 months is 231.00.
Each month's total comprises the sum of three months' worth of ratings.

PVLA Financial Forecast

PVLA Earnings Forecast

Next quarter’s earnings estimate for PVLA is -$1.16 with a range of -$1.42 to -$0.83. The previous quarter’s EPS was -$1.20. PVLA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.
Next quarter’s earnings estimate for PVLA is -$1.16 with a range of -$1.42 to -$0.83. The previous quarter’s EPS was -$1.20. PVLA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.

PVLA Sales Forecast

Next quarter’s sales forecast for PVLA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. PVLA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.
Next quarter’s sales forecast for PVLA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were ―. PVLA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PVLA has Performed in-line its overall industry.

PVLA Stock Forecast FAQ

What is PVLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Palvella Therapeutics, Inc.’s 12-month average price target is 231.00.
    What is PVLA’s upside potential, based on the analysts’ average price target?
    Palvella Therapeutics, Inc. has 77.68% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PVLA a Buy, Sell or Hold?
          Palvella Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Palvella Therapeutics, Inc.’s price target?
            The average price target for Palvella Therapeutics, Inc. is 231.00. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $270.00 ,the lowest forecast is $209.00. The average price target represents 77.68% Increase from the current price of $130.01.
              What do analysts say about Palvella Therapeutics, Inc.?
              Palvella Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of PVLA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.